Supernus Pharmaceuticals (SUPN) 2024 Wells Fargo Healthcare Conference summary

Business overview and strategy

• Focuses on CNS biopharmaceuticals with revenues guided at $600–$625 million and profitability maintained.

• Dual growth strategy: strong internal R&D heritage and targeted external acquisitions.

• Commercializes internally developed products and prioritizes operational efficiency and product synergy.

• Successfully transitioned from legacy products losing exclusivity to new launches while sustaining revenue.

• Maintains a balance between R&D investment and commercial infrastructure to support growth.

Qelbree and ADHD market dynamics

• Qelbree, a novel non-stimulant for ADHD, is gaining traction in both adult and pediatric segments.

• Adult ADHD market is dominated by stimulants; Qelbree is often introduced alongside stimulants and then titrated.

• Awareness campaigns leverage influencers to boost engagement and highlight non-stimulant benefits.

• Pediatric prescriptions grew 22% last quarter, with adult up 26%; market share remains early at 1.4%.

• ADHD market rebounded to 8% growth YTD after a soft prior year, with back-to-school season prioritized.

Legacy products and generic competition

• Oxtellar XR and Trokendi XR expected to generate $135–$145 million combined in 2023.

• Trokendi XR prescriptions have declined ~50% post-generic entry; Oxtellar XR faces first generic in September.

• Generic erosion in epilepsy is slower due to patient loyalty, but 80–90% loss is expected over 1–2 years.